Harvard Bioscience, Inc.
HBIO
$5.37
-$0.18-3.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -357.07% | -278.03% | -437.61% | -564.88% | -263.25% |
| Total Depreciation and Amortization | -16.93% | -11.42% | -4.09% | -0.38% | 2.27% |
| Total Amortization of Deferred Charges | 304.28% | 166.22% | 88.57% | 38.57% | 16.79% |
| Total Other Non-Cash Items | 701.92% | 536.21% | 691.27% | 599.06% | 13.14% |
| Change in Net Operating Assets | 8,627.69% | 96.85% | 2.08% | -75.42% | -98.59% |
| Cash from Operations | 367.29% | 112.79% | -28.16% | -77.80% | -89.73% |
| Capital Expenditure | 52.42% | 65.02% | 28.96% | -13.72% | -47.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -146.54% | -150.24% | -155.43% | 789.32% | 348.57% |
| Cash from Investing | -38.62% | 10.78% | -102.85% | 22.06% | 25.29% |
| Total Debt Issued | 354.55% | -100.00% | -56.95% | 14.55% | 95.56% |
| Total Debt Repaid | -335.67% | 63.04% | 70.53% | 57.46% | 43.00% |
| Issuance of Common Stock | -87.63% | -51.29% | -45.85% | -56.60% | -59.14% |
| Repurchase of Common Stock | 72.96% | 71.05% | 72.17% | 74.94% | 77.13% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2,280.12% | -326.71% | -- | -- | -- |
| Cash from Financing | -885.50% | -76.37% | 77.85% | 97.28% | 98.92% |
| Foreign Exchange rate Adjustments | 765.00% | 1,212.50% | 286.64% | 164.22% | 56.25% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,674.86% | 391.57% | 1,329.71% | 177.04% | 22.22% |